Literature DB >> 27638516

Evaluation of fibrosis and inflammation in diffuse liver diseases using intravoxel incoherent motion diffusion-weighted MR imaging.

Manuela França1, Luis Martí-Bonmatí2, Ángel Alberich-Bayarri2, Pedro Oliveira3,4, Susana Guimaraes5, João Oliveira6, João Amorim6, Javier Sanchez Gonzalez7, José Ramón Vizcaíno8, Helena Pessegueiro Miranda4,9.   

Abstract

PURPOSE: The purpose of the study was to evaluate the role of intravoxel incoherent motion (IVIM) diffusion model for the assessment of liver fibrosis and inflammation in diffuse liver disorders, also considering the presence of liver steatosis and iron deposits.
METHODS: Seventy-four patients were included, with liver biopsy and a 3 Tesla abdominal magnetic resonance imaging examination, with an IVIM diffusion-weighted sequence (single-shot spin-echo echo-planar sequence, with gradient reversal fat suppression; 6 b-values: 0, 50, 200, 400, 600, and 800 s/mm2). Histological evaluation comprised the Ishak modified scale, for grading inflammation and fibrosis, plus steatosis and iron loading classification. The liver apparent diffusion coefficient (ADC) and IVIM parameters (D, D*, f) were calculated from the IVIM images. The relationship between IVIM parameters and histopathological scores were evaluated by ANOVA and Spearman correlation tests. A test-retest experiment assessed reproducibility and repeatability in 10 healthy volunteers and 10 randomly selected patient studies.
RESULTS: ADC and f values were lower with higher fibrosis stages (p = 0.009, p = 0.006, respectively) and also with higher necro-inflammatory activity grades (p = 0.02, p = 0.017, respectively). Considered together, only fibrosis presented a significant effect on ADC and f measurements (p < 0.05), whereas inflammation had no significant effect (p > 0.05). A mild correlation was found between ADC and f with fibrosis (R S = -0.32 and R S = -0.38; p < 0.05) and inflammation (R S = -0.31 and R S = -0.32, p < 0.05; respectively). The AUROC for ADC and f measurements with the different dichotomizations between fibrosis or inflammation grades were only fair (0.670 to 0.749, p < 0.05). Neither D nor D* values were significantly different between liver fibrosis or inflammation grades. D measurements were significantly different across histologic grades of steatosis (p < 0.001) and iron overload (p < 0.001), whereas f measurements showed significant differences across histologic steatosis grades (p = 0.005). There was an excellent agreement between the different readers for ADC, f, and D.
CONCLUSIONS: Although fibrosis presented a significant effect on ADC and f, IVIM measurements are not accurate enough to stage liver fibrosis or necro-inflammatory activity in diffuse liver diseases. D values were influenced by steatosis and iron overload.

Entities:  

Mesh:

Year:  2017        PMID: 27638516     DOI: 10.1007/s00261-016-0899-0

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  13 in total

1.  Liver fibrosis: stretched exponential model outperforms mono-exponential and bi-exponential models of diffusion-weighted MRI.

Authors:  Nieun Seo; Yong Eun Chung; Yung Nyun Park; Eunju Kim; Jinwoo Hwang; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

Review 2.  Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation.

Authors:  Yáo T Li; Jean-Pierre Cercueil; Jing Yuan; Weitian Chen; Romaric Loffroy; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2017-02

Review 3.  Diffusion-weighted imaging and texture analysis: current role for diffuse liver disease.

Authors:  Sofia Gourtsoyianni; Joao Santinha; Celso Matos; Nikolaos Papanikolaou
Journal:  Abdom Radiol (NY)       Date:  2020-10-16

Review 4.  Topics on quantitative liver magnetic resonance imaging.

Authors:  Yì Xiáng J Wáng; Xiaoqi Wang; Peng Wu; Yajie Wang; Weibo Chen; Huijun Chen; Jianqi Li
Journal:  Quant Imaging Med Surg       Date:  2019-11

5.  IVIM with fractional perfusion as a novel biomarker for detecting and grading intestinal fibrosis in Crohn's disease.

Authors:  Meng-Chen Zhang; Xue-Hua Li; Si-Yun Huang; Ren Mao; Zhuang-Nian Fang; Qing-Hua Cao; Zhong-Wei Zhang; Xu Yan; Min-Hu Chen; Zi-Ping Li; Can-Hui Sun; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

6.  A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.

Authors:  Zhong-Wei Chen; Huan-Ming Xiao; Xinjian Ye; Kun Liu; Rafael S Rios; Kenneth I Zheng; Yi Jin; Giovanni Targher; Christopher D Byrne; Junping Shi; Zhihan Yan; Xiao-Ling Chi; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 7.  Quantitative magnetic resonance imaging for chronic liver disease.

Authors:  Guilherme Moura Cunha; Patrick J Navin; Kathryn J Fowler; Sudhakar K Venkatesh; Richard L Ehman; Claude B Sirlin
Journal:  Br J Radiol       Date:  2021-02-26       Impact factor: 3.629

8.  Evaluation of Regional Variability and Measurement Reproducibility of Intravoxel Incoherent Motion Diffusion Weighted Imaging Using a Cardiac Stationary Phase Based ECG Trigger Method.

Authors:  Zhiming Xiang; Zhu Ai; Jianke Liang; Guijin Li; Xiaolei Zhu; Xu Yan
Journal:  Biomed Res Int       Date:  2018-04-17       Impact factor: 3.411

9.  Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children.

Authors:  Hyun Joo Shin; Haesung Yoon; Myung-Joon Kim; Seok Joo Han; Hong Koh; Seung Kim; Mi-Jung Lee
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

Review 10.  Diffusion weighted magnetic resonance imaging of liver: Principles, clinical applications and recent updates.

Authors:  Anuradha Shenoy-Bhangle; Vinit Baliyan; Hamed Kordbacheh; Alexander R Guimaraes; Avinash Kambadakone
Journal:  World J Hepatol       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.